Practical ways to deal with the high burden of cardiovascular disease in hemodialysis patients
Keywords:
Renal dialysis, Chronic kidney failure, Cardiovascular diseases, Risk, Uremia, DiagnosisAbstract
Cardiovascular disease is the main cause of death among hemodialysis patients. Although uremia by itself may be considered to be a cardiovascular risk factor, a significant pro- portion of dialysis patients die because of cardiovascular disease not directly attributable to uremia. Indeed, many of the cardiovascular diseases and cardiovascular risk factors in these patients are common to those occurring in the general population and are amenable to intervention. Lack of proper medical care during the early stages of renal insufficiency and pres- ent-day dialysis routines, by failing to correct hypertension, hypervolemia and left ventricular hypertrophy in many patients, may also add to the cardiovascular burden. The author suggests that, in addition to early treatment and referral to a specialist, chronic renal failure patients should undergo intensive cardiovascular screening and treatment, and correction of cardiovascular risk factors based on guidelines established for the general population.
Downloads
References
Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154-69.
Zatz R, Romao JE Jr, Noronha IL. Nephrology in Latin America, with special emphasis on Brazil. Kidney Int Suppl. 2003;(83):S131-4.
Locatelli F, Del Vecchio L, Manzoni C. Morbidity and mortality on maintenance haemodialysis. Nephron. 1998;80(4):380-400.
De Lima JJ, Sabbaga E, Vieira ML, et al. Coronary angi- ography is the best predictor of events in renal transplant candidates compared with noninvasive testing. Hypertension. 2003;42(3):263-8.
De Lima JJ, Gowdak LH, Vieira ML, de Paula FJ, Ramires JA, Krieger EM. Diabetes increases cardiovascular morbidity and mortality in patients with end-stage renal disease even in the absence of significant coronary artery disease. [Abstract] Circulation. 2003;108(17 Suppl):S719.
Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S142-56.
De Lima JJ, Sesso R, Abensur H, et al. Predictors of mortality in long-term haemodialysis patients with a low prevalence of comorbid conditions. Nephrol Dial Transplant. 1995;10(9):1708-13.
Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 1999;34(4):1348-59.
Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32(5):853-906.
Covic A, Gusbeth-Tatomir P, Goldsmith DJ. The challenge of cardiovascular risk factors in end-stage renal disease. J Nephrol. 2003;16(4):476-86.
Longenecker JC, Coresh J, Powe NR, et al. Traditional cardio- vascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol. 2002;13(7):1918-27.
Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardio- vascular disease risks in chronic hemodialysis patients. Kidney Int. 2000;58(1):353-62.
Gowdak LHW, Paula FJ, Giorgi DMA, Vieira MLC, Krieger EM, De Lima JJG. Doença cardiovascular e fatores de risco car- diovascular em candidatos a transplante renal. [Cardiovascular disease and risk factors in candidates for renal transplantation]. Arq Bras Cardiol. 2005;84(2):156-160.
Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int. 1996;49(5):1428-34.
Foley RN. Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial. 2003;16(2):111-7.
Innes A, Rowe PA, Burden RP, Morgan AG. Early deaths on renal replacement therapy: the need for early nephrological referral. Nephrol Dial Transplant. 1992;7(6):467-71.
Sesso R, Belasco AG. Late diagnosis of chronic renal failure and mortality on maintenance dialysis. Nephrol Dial Transplant. 1996;11(12):2417-20.
Ifudu O, Dawood M, Homel P, Friedman EA. Excess morbid- ity in patients starting uremia therapy without prior care by a nephrologist. Am J Kidney Dis. 1996;28(6):841-5.
Sesso R, Yoshihiro MM, Ajzen H. Late diagnosis of chronic renal failure and the quality of life during dialysis treatment. Braz J Med Biol Res. 1996;29(10):1283-9.
Berthoux F, Jones E, Gellert R, Mendel S, Saker L, Briggs D. Epidemiological data of treated end-stage renal failure in the European Union (EU) during the year 1995: report of the Eu- ropean Renal Association Registry and the National Registries. Nephrol Dial Transplant. 1999;14(10):2332-42.
Vanholder RC, Ringoir SM. Adequacy of dialysis: a critical analysis. Kidney Int. 1992;42(3):540-58.
Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347(25):2010-9.
Valderrabano F. Weekly duration of dialysis treatment - does it matter for survival? Nephrol Dial Transplant. 1996;11(4):569-72.
Charra B, Laurent G, Chazot C, Jean G, Terrat JC, Vanel T. Hemodialysis trends in time, 1989 to 1998, independent of dose and outcome. Am J Kidney Dis. 1998;32(6 Suppl 4):S63-70.
Charra B, Calemard M, Laurent G. Importance of treatment time and blood pressure control in achieving long-term survival on dialysis. Am J Nephrol. 1996;16(1):35-44.
Raj DS, Charra B, Pierratos A, Work J. In search of ideal hemodialysis: is prolonged frequent dialysis the answer? Am J Kidney Dis. 1999;34(4):597-610.
Katzarski KS, Charra B, Luik AJ, et al. Fluid state and blood pressure control in patients treated with long and short haemo- dialysis. Nephrol Dial Transplant. 1999;14(2):369-75.
Curtis J. Daily short and nightly nocturnal home hemodialysis: state of the art. Dial Transplant. 2004;33(2):64-71.
Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 2001;104(13):1577-9.
Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis. 2001;37(3):484-9.
Chow FY, Polkinghorne KR, Chadban SJ, Atkins RC, Kerr PG. Cardiovascular risk in dialysis patients: a comparison of risk factors and cardioprotective therapy between 1996 and 2001. Nephrology (Carlton). 2003;8(4):177-83.
Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42(2):201-8.
Goldsmith DJ, Covic A. Coronary artery disease in uremia: Etiology, diagnosis, and therapy. Kidney Int. 2001;60(6):2059-78.
Ramos EL, Kasiske BL, Alexander SR, et al. The evaluation of candidates for renal transplantation. The current practice of
U.S. transplant centers. Transplantation. 1994;57(4):490-7.
Mittal SK, Kowalski E, Trenkle J, et al. Prevalence of hy- pertension in a hemodialysis population. Clin Nephrol. 1999;51(2):77-82.
Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hyperten- sion in chronic hemodialysis patients in the United States. Am J Med. 2003;115(4):291-7.
De Lima JJ, Vieira ML, Abensur H, Krieger EM. Baseline blood pressure and other variables influencing survival on haemodi- alysis of patients without overt cardiovascular disease. Nephrol Dial Transplant. 2001;16(4):793-7.
Chazot C, Charra B, Laurent G, et al. Interdialysis blood pressure control by long haemodialysis sessions. Nephrol Dial Transplant. 1995;10(6):831-7.
De Lima JJ, Lopes HF, Grupi CJ, et al. Blood pressure influences the occurrence of complex ventricular arrhythmia in hemodi- alysis patients. Hypertension. 1995;26(6 Pt 2):1200-3.
Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989;36(2):286-90.
De Lima JJ, Abensur H, Krieger EM, Pileggi F. Arterial blood pressure and left ventricular hypertrophy in haemodialysis patients. J Hypertens. 1996;14(8):1019-24.
Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114(5):345-52.
De Lima JJ, Abensur H, Bernardes-Silva H, Bellotti G, Pileggi
F. Role of arterial hypertension in left ventricle hypertrophy in hemodialysis patients: an echocardiographic study. Cardiology. 1992;80(3-4):161-7.
Cannella G, Paoletti E, Delfino R, Peloso G, Molinari S, Traverso GB. Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int. 1993;44(4):881-6.
Tucker B, Fabbian F, Giles M, Johnston A, Baker LR. Reduction of left ventricular mass index with blood pressure reduction in chronic renal failure. Clin Nephrol. 1999;52(6):377-82.
De Lima JJ, Vieira ML, Viviani LF, et al. Long-term impact of renal transplantation on carotid artery properties and on ventricular hypertrophy in end-stage renal failure patients. Nephrol Dial Transplant. 2002;17(4):645-51.
Kaysen GA. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol. 2001;12(7):1549-57.
Marcen R, Teruel JL, de la Cal MA, Gamez C. The impact of malnutrition in morbidity and mortality in stable haemodialysis patients. Spanish Cooperative Study of Nutrition in Hemodi- alysis. Nephrol Dial Transplant. 1997;12(11):2324-31.
Aparicio M, Cano N, Chauveau P, et al. Nutritional status of haemodialysis patients: a French national cooperative study. French Study Group for Nutrition in Dialysis. Nephrol Dial Transplant. 1999;14(7):1679-86.
Avram MM, Bonomini LV, Sreedhara R, Mittman N. Predictive value of nutritional markers (albumin, creatinine, cholesterol, and hematocrit) for patients on dialysis for up to 30 years. Am J Kidney Dis. 1996;28(6):910-7.
De Lima JJ, da Fonseca JA, Godoy AD. Baseline variables as- sociated with early death and extended survival on dialysis. Ren Fail. 1998;20(4):581-7.
Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55(2):648-58.
Suliman ME, Qureshi AR, Barany P, et al. Hyperhomocys- teinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int. 2000;57(4):1727-35.
